Metformin remains one of the most widely used and enduring therapies in modern medicine. This book provides a rigorous and evidence-based examination of its pharmacology, clinical foundations, and public health significance, offering a structured perspective on its central role in the management of type 2 diabetes.

Based on decades of clinical trials, outcome studies, and long-term follow-up data, the chapters trace the development of metformin from early uncertainty to its current position as a foundational therapy. Its established profile of efficacy, safety, and affordability has supported its sustained use in clinical practice and its contribution to reducing diabetes-related complications and improving long-term outcomes.

The text extends beyond glycemic control to examine broader clinical and population-level implications, including its role in disease prevention, cardiovascular outcomes, and areas of ongoing investigation such as metabolic health, inflammatory pathways, and aging-related processes. These discussions are grounded in current evidence while acknowledging evolving research directions.

Integrating scientific analysis with practical relevance, the volume brings together perspectives across pharmaceutical science, clinical medicine, and public health. It emphasizes the importance of accessible, effective therapies in addressing the growing global burden of metabolic disease.

By combining pharmacologic detail with long-term outcome evidence and public health context, this work serves as a comprehensive resource for clinicians, researchers, and students. It also contributes to ongoing discussions on evidence-based practice, healthcare accessibility, and the future direction of metabolic medicine in diverse healthcare systems.